Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Remission induction therapy: the more intensive the better?

T Büchner1, W Hiddemann, W Berdel

  • 1Department of Medicine, Hematology/Oncology, University of Münster, Germany. buechnr@uni-muenster.de

Cancer Chemotherapy and Pharmacology
|October 6, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification.

Leukemia·2024
Same author

Role and responsibility of oncologists in assisted suicide. Practice and views among members of the German Society of Haematology and Medical Oncology.

ESMO open·2021
Same author

Reductions in body weight and insulin resistance are not associated with changes in grey matter volume or cortical thickness during the PREVIEW study.

Journal of the neurological sciences·2019
Same author

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2018
Same author

Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.

Leukemia research·2017
Same author

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Leukemia·2017

Intensive induction therapy improves outcomes for acute myeloid leukemia (AML) patients, especially those with poor-risk factors. Higher doses of cytarabine (AraC) and daunorubicin enhance response rates and survival in both younger and older adults.

Area of Science:

  • Hematology
  • Oncology
  • Cancer Therapeutics

Background:

  • Intensive induction therapy for acute myeloid leukemia (AML) differs significantly from post-remission strategies.
  • Induction therapy targets naive leukemia cells, distinct from resistant cells in remission.

Purpose of the Study:

  • To evaluate the impact of intensified induction therapy on AML treatment outcomes.
  • To investigate dose-response effects of chemotherapy agents during induction.

Main Methods:

  • Analysis of treatment strategies including high-dose cytarabine (AraC) and double induction in patients up to 60 years.
  • Evaluation of daunorubicin dosage within the thioguanine/AraC/daunorubicin (TAD) regimen for patients aged 60 and older.
  • Assessment of outcomes based on risk stratification (karyotype, LDH, response delay).

Related Experiment Videos

Main Results:

  • Intensified induction with high-dose AraC improved survival in poor-risk AML patients.
  • Higher daunorubicin dosage (60 vs 30 mg/m2) in the TAD regimen significantly increased response rates and survival in older patients.
  • Demonstrated that intensive induction therapy can improve prognosis in both younger and older AML patients.

Conclusions:

  • Intensive induction therapy, particularly with higher chemotherapy doses, offers significant survival benefits for AML patients, including poor-risk groups.
  • While intensive induction shows promise, cumulative toxicity (e.g., prolonged aplasia from high-dose AraC) necessitates careful management.
  • Future strategies may involve high-dose chemotherapy with stem-cell rescue in remission to further improve outcomes for AML patients.